Neurology News

Oragenics Inc. and Odyssey Health Inc. have announced an agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies.

Researchers reported that HF was independently prognostic of both cardiac and cerebral microvascular dysfunction predictive of impaired cognitive function.

Healio is pleased to announce and congratulate the 2023 honorees of its peer-to-peer recognition program, Healio Honors.

Genentech has announced positive results from its primary analysis of an ongoing study assessing safety and efficacy of Evrysdi in babies with pre-symptomatic spinal muscular atrophy.

In a diverse cohort of Hispanic/Latino individuals, longer sleep duration was associated with lower total brain and gray matter volume, according to research published in Alzheimer’s & Dementia.

Investigational antifungal fosmanogepix has been added as a first-line treatment in recommendations penned following the emergence of an ongoing fungal meningitis outbreak, researchers said.

A Bay Area pharmaceutical firm has announced positive data from a phase 3 clinical trial evaluating Chenodal tablets to treat adults with cerebrotendinous xanthomatosis, an autosomal, recessive, progressive genetic disorder.

A Manhattan-based biopharmaceutical firm has announced positive topline data from its phase 2 trial of a novel formulation of intranasal racemic ketamine for acute suicidal ideation and behavior in adults with major depressive disorder.

We’ve discussed non-compete restrictions and possible exceptions in our previous blog entries. In addition to non-competes, you can expect that the buyer of your practice will also expect you to agree to non-solicits and no-hires.

Brain-based biomarkers of likely drug response were associated with a greater mean reduction in reported PTSD symptoms in a study of patients treated with ALTO-100.